-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Reinstates Overweight on Amneal Pharmaceuticals, Announces $22 Price Target

Benzinga·08/26/2026 14:01:33
Listen to the news
JP Morgan analyst Chris Schott reinstates Amneal Pharmaceuticals (NASDAQ:AMRX) with a Overweight and announces $22 price target.